Veracyte Inc. logo

Veracyte Inc. (VCYT)

Market Open
20 Jul, 14:32
NASDAQ (NMS) NASDAQ (NMS)
$
58. 41
-0.72
-1.2177%
$
4.55B Market Cap
- P/E Ratio
- Div Yield
161,204 Volume
-0.74 Eps
$ 59.13
Previous Close
Analysts:
Add Transaction
Day Range
58.05 59.83
Year Range
22.92 60.91
Want to track VCYT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.

Zacks | 2 months ago
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 2 months ago
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average

Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average

Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a short-term bullish trend.

Zacks | 2 months ago
Is Veracyte Stock the Right Pick for Your Portfolio Now?

Is Veracyte Stock the Right Pick for Your Portfolio Now?

VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.

Zacks | 3 months ago
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Zacks | 3 months ago
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT

Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT

Bamco Inc. NY lowered its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 645,621 shares of the biotechnology company's stock after selling 231,579 shares during the quarter. Bamco

Defenseworld | 4 months ago
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.

Zacks | 4 months ago
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Seekingalpha | 4 months ago
Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.

Zacks | 4 months ago
Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?

Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 4 months ago
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings

Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings

VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.

Zacks | 5 months ago
Loading...
Load More